S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54

Allena Pharmaceuticals Stock Forecast, Price & News

-0.01 (-7.75%)
(As of 06/28/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
23.82 million shs
Average Volume
6.80 million shs
Market Capitalization
$12.82 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Stock Forecast (MarketRank)

Overall MarketRank

1.73 out of 5 stars

Medical Sector

891st out of 1,433 stocks

Biological Products, Except Diagnostic Industry

135th out of 217 stocks

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
Allena Pharmaceuticals logo

About Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

ALNA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-48.66 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.23 per share


Free Float
Market Cap
$12.82 million
Not Optionable

Allena Pharmaceuticals Frequently Asked Questions

Should I buy or sell Allena Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Allena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNA, but not buy additional shares or sell existing shares.
View analyst ratings for Allena Pharmaceuticals
or view top-rated stocks.

What is Allena Pharmaceuticals' stock price forecast for 2022?

3 brokerages have issued 1-year target prices for Allena Pharmaceuticals' shares. Their ALNA stock forecasts range from $3.00 to $11.00. On average, they predict Allena Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 5,782.4% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Allena Pharmaceuticals' stock price performed in 2022?

Allena Pharmaceuticals' stock was trading at $0.5925 at the start of the year. Since then, ALNA shares have decreased by 79.9% and is now trading at $0.1190.
View the best growth stocks for 2022 here

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Allena Pharmaceuticals

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02.
View Allena Pharmaceuticals' earnings history

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Dr. Alexey L. Margolin Ph.D., Co-Founder & Chairman (Age 69, Pay $70k)
  • Dr. Louis Brenner M.B.A., M.D., Pres, CEO & Director (Age 52, Pay $576.86k)
  • Dr. Richard D. Katz, CFO, Principal Financial Officer & Principal Accounting Officer (Age 58, Pay $400.67k)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 57)
  • Mr. Geoffrey A. Swire, Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer (Age 49)
  • Mr. Hugh Wight, Sr. VP of Technical Operations
  • Dr. Alicja Januszewicz Ph.D., VP of People & Culture
  • Dr. David J. Clark, Chief Medical Officer (Age 57)
  • Mr. Stephen Yu, Sr. VP of Corp. Quality

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.88%) and Frazier Management LLC (1.14%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner.
View institutional ownership trends for Allena Pharmaceuticals

Which major investors are selling Allena Pharmaceuticals stock?

ALNA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Frazier Management LLC. Company insiders that have sold Allena Pharmaceuticals company stock in the last two years include Edward Wholihan, and Louis Md Brenner.
View insider buying and selling activity for Allena Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $0.12.

How much money does Allena Pharmaceuticals make?

Allena Pharmaceuticals (NASDAQ:ALNA) has a market capitalization of $12.82 million.

How many employees does Allena Pharmaceuticals have?

Allena Pharmaceuticals employs 35 workers across the globe.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The official website for Allena Pharmaceuticals is www.allenapharma.com. The company can be reached via phone at (617) 467-4577, via email at [email protected], or via fax at 617-916-1871.

This page (NASDAQ:ALNA) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.